Page last updated: 2024-09-03

gefitinib and naltrexone

gefitinib has been researched along with naltrexone in 7 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(naltrexone)
Trials
(naltrexone)
Recent Studies (post-2010) (naltrexone)
5,2315662,9198,7451,2282,642

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)naltrexone (IC50)
Cytochrome P450 2D6Homo sapiens (human)1
Delta-type opioid receptorMus musculus (house mouse)0.0051
Delta-type opioid receptorRattus norvegicus (Norway rat)0.0063
Kappa-type opioid receptorMus musculus (house mouse)0.006
Mu-type opioid receptorRattus norvegicus (Norway rat)0.0005
Kappa-type opioid receptorRattus norvegicus (Norway rat)0.0005
Mu-type opioid receptorHomo sapiens (human)0.006
Delta-type opioid receptorHomo sapiens (human)0.0319
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.0093
Kappa-type opioid receptorHomo sapiens (human)0.0377
Mu-type opioid receptorMus musculus (house mouse)0.0076
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.0004

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ekins, S; Williams, AJ; Xu, JJ1
Dalvie, D; Loi, CM; Smith, DA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Nagase, H; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK1

Reviews

1 review(s) available for gefitinib and naltrexone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for gefitinib and naltrexone

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mutation, Missense; Naltrexone; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Opioid, kappa; Signal Transduction; STAT3 Transcription Factor

2012